IVEVF News and Press, Inventiva From 11/13/25

IVEVF - Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfun...

IVEVF - Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfun...

IVEVF - Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfun...

IVEVF - Inventiva announces $125M U.S. public offering of ADSs

2025-11-12 16:42:09 ET More on Inventiva S.A Inventiva S.A. (IVA) Analyst/Investor Day - Slideshow Inventiva S.A. (IVA) Analyst/Investor Day Transcript MASH drug developers rise as FDA accepts lenient trial requirement Inventiva surges as Piper Sandler issues...

IVEVF - Inventiva announces launch of public offering

Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfun...

IVEVF - Combined General Meeting of November 27, 2025 - Availability of the preparatory documents

Daix (France), New York City (New York, United States), November 6, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for...

IVEVF - Statement of total voting rights and shares forming the company's share capital as October 20, 2025

Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www . i n v e n t i v a p ha r m a. c om (1) The total number of gross (or &#...

IVEVF - Inventiva Announces the Implementation of a New ATM Program

Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the t...

IVEVF - Inventiva S.A. (IVA) Analyst/Investor Day Transcript

2025-10-08 19:16:38 ET Inventiva S.A. (IVA) Analyst/Investor Day October 8, 2025 11:30 AM EDT Company Participants Mark Pruzanski Andrew Obenshain - CEO & Director Jason Campagna - President of Research and Development & Chief Medical Officer Martine ...

IVEVF - Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025

Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 study Presentation of digital pathology data from preclinical studies with lanifibranor Daix (France), New York City (New York, United States), October 7, 2025 - In...

Company Name:	Inventiva
Stock Symbol:	IVEVF
Market:	OTC
Website:	inventivapharma.com